—NRG
— • —
$164.07
P/E
38.28
PEG
—
FCF Yield
—
Rev Growth YoY
+918.0% YoY
Gross Margin
2055.0%
Health Score
4/10
D/E Ratio
9.78
Confidence
LOW
Business Snapshot
The ticker and exchange identifiers are absent from this data payload, making it impossible to confirm the company's name, sector, or industry with certainty. The stock trades at $164.07 per share. Given the missing market capitalisation figure, cap tier cannot be formally assigned, though the combination of a $164 price point and the financial profile described below suggests a smaller or niche entity.
Financial Health
Score: 4/10
The financial picture here is deeply contradictory. On the surface, the gross margin of 2,055% and net margin of 281% appear extraordinary — but figures of this magnitude are almost certainly the result of accounting anomalies, restatements, or a very small revenue base producing distorted ratios rather than genuine operational excellence...
Risk Assessment
- DEBT: Debt/equity of 9.78x is severely elevated, creating meaningful refinancing and solvency risk if earnings continue to deteriorate.
- EARNINGS DETERIORATION: Earnings growth of -1,771% YoY signals that top-line expansion is coming at a steep cost to profitability.
- DATA TRANSPARENCY: TTM Revenue, TTM Net Income, FCF, market cap, and DCF fair value are all absent, making a complete fundamental assessment impossible.
- TECHNICALS: A confirmed death cross (50-day MA crossing below 200-day MA) with price trading below both moving averages signals sustained bearish price momentum.
- VALUATION PREMIUM: P/E of 38.28x and EV/EBITDA of 61.77x leave little margin of safety if growth disappoints or macro conditions tighten.
---...
**Score: 4/10** The financial picture here is deeply contradictory. On the surface, the gross margin of 2,055% and net margin of 281% appear extraordinary — but figures of this magnitude are almost certainly the result of accounting anomalies, restatements, or a very small revenue base producing distorted ratios rather than genuine operational excellence. Debt/equity of 9.78x is severely elevated, indicating the company is heavily reliant on borrowed capital. Free cash flow is unavailable, removing the single most reliable indicator of whether the business can service its obligations without raising additional capital. ---
- **DEBT:** Debt/equity of 9.78x is severely elevated, creating meaningful refinancing and solvency risk if earnings continue to deteriorate. - **EARNINGS DETERIORATION:** Earnings growth of -1,771% YoY signals that top-line expansion is coming at a steep cost to profitability. - **DATA TRANSPARENCY:** TTM Revenue, TTM Net Income, FCF, market cap, and DCF fair value are all absent, making a complete fundamental assessment impossible. - **TECHNICALS:** A confirmed death cross (50-day MA crossing below 200-day MA) with price trading below both moving averages signals sustained bearish price momentum. - **VALUATION PREMIUM:** P/E of 38.28x and EV/EBITDA of 61.77x leave little margin of safety if growth disappoints or macro conditions tighten. ---
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives